Abstract
Background
Previous studies of psychological burden in low-dose CT (LDCT) lung
cancer screening trials may lack generalisability due to participation
bias and control arms having elevated distress.
Methods
Current and former smokers (n=787, aged 60–75) within a real-world
screening demonstration pilot completed measures of lung cancer worry at
three time points (T0: appointment,
T1: next day, T2: 3
months) and anxiety and depression at two time points
(T0and T2). A ‘screening
unaware’ community sample (n=383) with the same age and smoking
characteristics completed these measures once (T0).
Mean scores were compared by sample type and LDCT result.
Results
Compared with the community sample (T0), mean
scores were higher in the screening sample, and statistically
significantly increased in adjusted analyses, for lung cancer worry at
T0and T2(mean (M): 9.32;
95% CI 8.96 to 9.69 vs M: 11.34; 11.09 to 11.59 and M: 11.88; 11.49 to
12.27), for anxiety at T0and
T2(M: 3.32; 2.94 to 3.70 vs M: 4.73; 4.42 to
5.04 and M: 5.78; 5.33 to 6.23) and depression at
T2(M: 3.85; 3.44 to 4.27 vs M: 4.15; 3.76 to
4.55). Scores were highest for those with indeterminate (eg,
T2anxiety M: 6.93; 5.65 to 8.21) and incidental
findings (primary care follow-up M: 5.34; 4.67 to 6.02) and those
ineligible for screening (M: 6.51; 5.25 to 7.77). Being female, younger,
not in paid employment, not married/cohabiting with a partner and lower
education predicted poorer psychological outcomes at
T0, but not T2after
adjusting for baseline scores. Mean scores remained within ‘normal’
clinical ranges.
Conclusion
Psychological distress was raised among high-risk individuals
undergoing LDCT screening in a real-world setting, but overall
differences were unlikely to be clinically meaningful. It will be
critical to monitor the psychological impact of services longitudinally
across diverse settings, including subgroups vulnerable to clinically
elevated distress.
Trial registration
The Lung Screen Uptake Trial was registered prospectively with the
International Standard Registered Clinical/soCial sTudy (ISRCTN)
(Number:NCT21774741) on 23
September 2015 and the National Institutes of Health ClinicalTrials.gov
database (NCT02558101) on 22 September 2015.
Funder
Cancer
Research UK
Roy
Castle Lung Cancer Foundation
Wellcome
Trust
Subject
Pulmonary and Respiratory Medicine
Reference29 articles.
1. Cancer Research UK . Lung cancer mortality
statistics. Available:
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality#heading-Zero
2. Cancer Research UK . Lung cancer incidence
statistics. Available:
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence#heading-Three
3. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
4. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
5. Reduced lung-cancer mortality with volume CT screening in a randomized trial;de Koning;N Engl J Med,2020